CINECA IRIS Institutional Research Information System

VALERIO, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2011
EU - Europa 1375
AS - Asia 274
AF - Africa 65
SA - Sud America 15
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3745
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1973
DE - Germania 408
SE - Svezia 335
IT - Italia 232
CN - Cina 130
BG - Bulgaria 128
GB - Regno Unito 121
AT - Austria 73
CI - Costa d'Avorio 51
VN - Vietnam 50
IN - India 36
TR - Turchia 30
CA - Canada 27
RU - Federazione Russa 20
JP - Giappone 10
PL - Polonia 10
FI - Finlandia 9
BE - Belgio 7
GR - Grecia 7
CR - Costa Rica 6
UA - Ucraina 6
FR - Francia 5
KR - Corea 5
MA - Marocco 5
NL - Olanda 5
AU - Australia 4
BR - Brasile 4
PK - Pakistan 4
CH - Svizzera 3
EC - Ecuador 3
EG - Egitto 3
ID - Indonesia 3
MX - Messico 3
NG - Nigeria 3
CL - Cile 2
HK - Hong Kong 2
PE - Perù 2
SV - El Salvador 2
VE - Venezuela 2
ZA - Sudafrica 2
A1 - ???statistics.table.value.countryCode.A1??? 1
AR - Argentina 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
IE - Irlanda 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
PH - Filippine 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3745
Salva come PNG Salva come JPEG
Città #
Chandler 323
Fairfield 258
Woodbridge 169
Houston 142
Sofia 128
Seattle 126
Wilmington 121
Cambridge 96
Ashburn 91
Princeton 72
Vienna 71
Ann Arbor 66
Abidjan 51
Beijing 51
Lawrence 51
London 47
Medford 38
Frankfurt am Main 36
Redwood City 30
Serra 30
Boulder 29
Dong Ket 25
Dearborn 22
Redmond 22
Bremen 21
Pisa 21
San Diego 21
Ottawa 20
Des Moines 17
Scandicci 12
Chiesina Uzzanese 10
Rome 10
Izmir 9
Hefei 8
Lancaster 8
Nanchang 8
Nanjing 8
Milan 7
Tianjin 7
Brussels 6
Kocaeli 6
San José 6
Shanghai 6
Shenyang 6
Amsterdam 5
Istanbul 5
Jiaxing 5
Ningbo 5
Norwalk 5
Phoenix 5
Salt Lake City 5
Samsun 5
Duncan 4
Jinan 4
Montreal 4
Napoli 4
Zhengzhou 4
Atakum 3
Bangalore 3
Cleveland 3
Hebei 3
Jakarta 3
Kunming 3
Lagos 3
Los Angeles 3
Munich 3
Stuttgart 3
Tokyo 3
Calcinaia 2
Changsha 2
Crick 2
Florence 2
Geneva 2
Gurgaon 2
Haikou 2
Hyderabad 2
Islamabad 2
Johannesburg 2
Lima 2
Lucca 2
Moncalieri 2
Monte Compatri 2
Moscow 2
Palo Alto 2
Pian Camuno 2
Quito 2
Remington 2
Sacile 2
San Francisco 2
San Salvador 2
Santiago 2
Scafati 2
Scandiano 2
Seoul 2
Seveso 2
Toronto 2
Anchorage 1
Ardea 1
Atikokan 1
Bogotá 1
Totale 2465
Salva come PNG Salva come JPEG
Nome #
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 153
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 141
Targeted Therapy in Thyroid Cancer: State of the Art 137
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 132
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 120
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 119
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 119
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 115
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 115
Il carcinoma tiroideo: nuove prospettive terapeutiche. 113
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 106
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 106
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 103
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 98
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 96
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 95
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 91
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 90
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 89
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 86
null 84
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 80
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 77
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 74
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 74
Role of oxidative stress in radio-induced DNA damage and in RET/PTC rearrangement in papillary thyroid cancer 72
DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER 72
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 69
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 67
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 64
Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study 62
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 60
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 53
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 52
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 49
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 46
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 46
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 44
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 43
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 42
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 42
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 42
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 40
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 37
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer 36
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 31
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 30
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 30
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 30
FDG-PET/CT Correlates with the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival 26
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 26
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 24
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 22
Totale 3870
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201875 0000 00 00 12162819
2018/2019313 165317 158 3614 28407655
2019/20201109 65698591 111127 12477 989214921
2020/2021471 59205914 1876 1928 35403172
2021/2022607 16141425 13283 1427 393746160
2022/20231070 1621879089 110124 40108 160000
Totale 3870